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Background. There are an estimated 2.6 million stillbirths each year, many of which are due to infections, especially in low- and 
middle-income contexts. This paper, the eighth in a series on the burden of group B streptococcal (GBS) disease, aims to estimate 
the percentage of stillbirths associated with GBS disease.
Methods. We conducted systematic literature reviews (PubMed/Medline, Embase, Literatura Latino-Americana e do Caribe em 
Ciências da Saúde, World Health Organization Library Information System, and Scopus) and sought unpublished data from investi-
gator groups. Studies were included if they reported original data on stillbirths (predominantly ≥28 weeks’ gestation or ≥1000 g, with 
GBS isolated from a sterile site) as a percentage of total stillbirths. We did meta-analyses to derive pooled estimates of the percentage 
of GBS-associated stillbirths, regionally and worldwide for recent datasets.
Results. We included 14 studies from any period, 5 with recent data (after 2000). There were no data from Asia. We estimated 
that 1% (95% confidence interval [CI], 0–2%) of all stillbirths in developed countries and 4% (95% CI, 2%–6%) in Africa were asso-
ciated with GBS.
Conclusions. GBS is likely an important cause of stillbirth, especially in Africa. However, data are limited in terms of geographic 
spread, with no data from Asia, and cases worldwide are probably underestimated due to incomplete case ascertainment. More data, 
using standardized, systematic methods, are critical, particularly from low- and middle-income contexts where the highest burden 
of stillbirths occurs. These data are essential to inform interventions, such as maternal GBS vaccination.
Keywords. group B Streptococcus; stillbirth; stillborn; mortality; estimates.
 
There have been substantial reductions in under-5 childhood 
deaths worldwide, driven by the Millennium Development 
Goals, which ended in 2015 [1]. However, the burden of still-
births was not included in these goals and is considerable, with 
around 2.6 million stillbirths each year [2], similar to the num-
ber of deaths occurring during the neonatal period (2.7 million) 
[3]. Most stillbirths occur in low- and middle-income contexts, 
in sub-Saharan Africa (1.0 million) and South Asia (1.3 million).
Data on the causes of stillbirth are limited, and comparability 
of causes is challenging due to multiple classification systems [4]. 
Obstetric emergencies, including antepartum hemorrhage and 
maternal hypertensive disorders (preeclampsia and eclampsia), 
are important contributors [4]. Infection is also important, but 
apart from estimates for the contribution of maternal malaria, 
syphilis, and human immunodeficiency virus (HIV) [4], data 
on infectious causes of stillbirth are sparse [5].
Group B Streptococcus (GBS; Streptococcus agalactiae) mater-
nal colonization of the genitourinary tract is common, occur-
ring in approximately 10%–40% of women worldwide [6, 7]. 
Vertical transmission leads to high incidence of early onset 
(0–6  days of age) neonatal GBS disease (EOGBS), essentially 
(80%–90% of cases) manifesting within 24 hours after birth 
[8]. GBS has more recently been identified as an important 
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pathogen in neonatal disease in low-income contexts, including 
sub-Saharan Africa and India [9, 10].
In EOGBS and GBS-associated stillbirth, infection is likely 
due to ascending infection in utero from the maternal genito-
urinary tract, starting before delivery. Whole-genome sequenc-
ing studies demonstrate that GBS isolated at birth from the skin 
of newborns delivered by cesarean section are identical to those 
colonizing the mother. Furthermore, stillbirths with GBS iso-
lated from postmortem blood culture were genetically identical 
to maternal GBS colonizing isolates [11].
Understanding the contribution of GBS as a cause of still-
birth is important to design and implement preventive inter-
ventions. For EOGBS disease, 4 or more hours of intrapartum 
antibiotic prophylaxis, based either on maternal clinical risk 
factors or the presence of maternal GBS colonization from 
microbiological screening at 35–37 weeks’ gestation, is fre-
quently given in high-income contexts [12, 13]. However, 
this strategy is unlikely to prevent GBS-associated stillbirth 
occurring before labor and/or health facility attendance, where 
antibiotics could be administered. In contrast, maternal vacci-
nation could protect the fetus from invasive disease in utero. 
A trivalent GBS polysaccharide-protein conjugate vaccine was 
recently evaluated in phase 2 clinical trials among pregnant 
women [14].
We undertook a systematic review of the percentage of 
stillbirths associated with GBS worldwide as part of the total 
burden of GBS disease (Figure 1). This article is part of a sup-
plement estimating the burden of GBS disease in pregnant 
women, stillbirths, and infants, which is important in terms of 
public health policy [15]. This supplement includes systematic 
reviews and meta-analyses, which form input parameters to 
estimates, partly through a compartmental model [16]. These 
are reported individually according to international guidelines 
for improving estimation [17, 18]: maternal colonization [6], 
maternal GBS disease [19], preterm birth [20], use of intra-
partum antibiotic prophylaxis [12], risk of newborn disease 
[13], neonatal disease [10], neonatal encephalopathy [21], and 
impairment after neonatal disease [22]. These are used for esti-
mates of the burden of GBS in pregnant women, stillbirths, and 
infants worldwide [16].
The objectives of this review were (1) to undertake com-
prehensive, systematic literature reviews and meta-analyses to 
calculate the pooled percentage of stillbirths with evidence of 
GBS infection regionally and worldwide; (2) to use these data 
for estimates of the burden of GBS in pregnancy for women, 
stillbirth and infants; and (3) to evaluate gaps in the data and 
make recommendations to improve the data on GBS-associated 
stillbirth.
Figure 1. Group B Streptococcus (GBS)–associated stillbirth in disease schema for GBS, as described by Lawn et al [15].
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METHODS
This article is part of a wider study protocol entitled “Systematic 
estimates of the burden of GBS in pregnant women, stillbirths 
and infants worldwide.” It was submitted for ethical approval to 
the London School of Hygiene & Tropical Medicine (reference 
number 11966). We describe the general methods elsewhere; 
here we give details of methods specific to GBS-associated 
stillbirth.
Definitions
We used the World Health Organization definition of still-
birth—that is, birth of a fetus with no signs of life at ≥28 weeks’ 
gestation or weighing ≥1000  g [23]. Where gestational data 
were available, this was preferred as the birthweight threshold 
is not equivalent to 28 weeks’ gestation [24]. Confirmed cases 
of GBS-associated stillbirth were based on microbiological evi-
dence of invasive GBS disease, from a normally sterile site such 
as fetal blood (sampled from the umbilical cord or from the 
heart), lung aspirate, cerebrospinal fluid, or fetal tissues. Cases 
where GBS was only isolated from a potentially contaminated 
site (eg, placenta or amniotic fluid [other than by amniocente-
sis], gastric or tracheal aspirate) were not included.
Data Searches and Inputs
We identified data through systematic review of the published 
literature and through development of an investigator group ask-
ing clinicians, researchers, and relevant professional institutions 
worldwide. For this report, we did systematic literature searches 
of Medline, Embase, and Literatura Latino-Americana e do 
Caribe em Ciências da Saúde from 15 March 2015 to 1 February 
2017 to update a previous systematic review [25]. We did sys-
tematic literature searches of the World Health Organization 
Library Information System and Scopus on 1 February 2017. 
We searched databases with variants of terms related to “still-
birth/fetal mortality” and “group B Streptococcus.” Medical 
subject headings (MeSH) terms were used where possible (see 
Supplementary Table 1 for the full list of search terms). We 
did not apply language or date restrictions. We used snowball 
searches of article reference lists to identify additional studies 
[18]. Two independent investigators (A. C. S. and F. B. J.) per-
formed the database searches, screened titles for duplicates and 
for eligibility, and screened abstracts to assess their suitability 
for inclusion, and one investigator (A. C. S.) extracted data. The 
data extraction from full texts was compared to a recent system-
atic review [25] and, for any discrepancies, a second investigator 
(F. B. J.) reextracted the data.
Inclusion and Exclusion Criteria
We included studies having a defined population denomina-
tor, including all stillbirths in a facility, or occurring in a geo-
graphical location in a specified time period (Supplementary 
Table  2 for inclusion and exclusion criteria). We based case 
ascertainment on isolation of GBS identified through conven-
tional microbiological culture. We excluded studies where only 
stillbirths <28 weeks’ gestation were reported (outside of the 
World Health Organization definition), or where cultures were 
only taken from potentially nonsterile or contaminated sites.
Meta-analyses
Random-effects meta-analyses to estimate the percentage of 
GBS-associated stillbirth worldwide and by region were per-
formed using the DerSimonian and Laird method [26] for 
recent data (from the year 2000).
Sensitivity Analyses
Sensitivity analyses were done to assess (1) changes in time, 
and whether recent data (from 2000) differ in the percentage of 
GBS-associated stillbirth when studies reporting data from all 
years are included; and (2) changes by region and with time, and 
whether there was any difference in the proportion of stillbirth 
associated with GBS when studies from developed regions were 
categorized by year periods for median year of data collection.
RESULTS
Study Selection
We identified 303 records through the systematic searches; 14 
of these studies met the inclusion criteria. Six of the included 
studies (3 published articles [27–29] and 3 unpublished or 
updated datasets [30]) reported data collected from the year 
2000 onward (recent data), whereas 8 studies reported data col-
lected before 2000 (Figure 2 and Table 1) [31–37].
Study Characteristics
The characteristics of all 14 studies are summarized in Table 1. 
All were hospital based and included microbiological confirma-
tion of GBS from the fetus. Most (9/14 studies) were from devel-
oped countries, with 5 of 14 studies from sub-Saharan Africa. 
There were no studies from Asia or South America (Figure 3).
Of the 6 studies with data collection from the year 2000, 3 were 
from developed countries (Italy, England, and the United States) 
and 3 were from sub-Saharan Africa (Kenya, South Africa, and 
Mozambique). Study methods differed in the details of the micro-
biological evidence of GBS infection. In the largest study, from 
England [30], cases were diagnosed based on medical case records 
and autopsies. In the study from Italy [34], samples were taken 
from heart blood and in the study from the United States, sam-
ples were amniotic fluid taken by amniocentesis [29]. In the most 
recent studies from Kenya, South Africa, and Mozambique, the 
fetus was sampled after delivery: blood from the cord or a lung 
aspirate in the study from Kenya [27] and cord or heart-puncture 
blood sampling in the study from South Africa (personal commu-
nication, S. Madhi, April 2017) and the study from Mozambique 
examined multiple fetal organs, with GBS detection from both 
conventional culture and GBS polymerase chain reaction [41].
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GBS-Associated Stillbirth
The number of cases included overall was small; in studies that 
included data since 2000, there were 65 cases of confirmed 
GBS-associated stillbirth, from a total denominator of 893 
stillbirths (Table  1). The percentage of GBS-associated still-
births varied by region, being lower in developed countries 
with a pooled estimate of 1% (95% confidence interval [CI], 
0–2%) compared to 4% (95% CI, 2%–6%) in sub-Saharan 
Table 1. Group B Streptococcus–Associated Stillbirth: Characteristics of Studies and Data, All Years
Study, First Author Country Location Data Collection Year, Median Total Births Total Stillbirths
Total Infectious 
Stillbirths
Total GBS-
Associated 
Stillbirths
Hood [33] United States New Orleans 1958–1959 1958 NA 113 66 11
Bergqvist [39] Sweden Stockholm 1970–1975 1973 17 638 117 24 5
Christensen [40] Sweden Lund 1979–1980 1979 130 11 2 1
Ahlenius [32] Sweden Karolinska 1987–1989 1988 10 707 66 8 2
Tolockiene [31] Sweden Lund 1985–1994 1989 4130 117 32 2
Moyo [34] Zimbabwe Harare 1989–1991 1990 NA 66 43 8
Folgosa [35] Mozambique Maputo 1990–1991 1990 NA 58 41 0
Maleckiene [37] Lithuania Kaunas University 1996–1998 1997 NA 290 21 2
Embletona [30] England Newcastle 1981–2005 1992 906 068 179 139 37
Blackwell [29] United States Detroit 2000–2002 2001 NA 44 NA 1
Monari [28] Italy Modena 2005–2011 2009 NA 109 20 4
Seale [27] Kenya Kilifi 2013–2014 2013 NA 149 NA 4
Madhia South Africa Soweto 2014–2015 2014 NA 394 NA 16
Menéndez [41] Mozambique Maputo 2014 2014 NA 18 NA 3
Studies with all data collected before 2000 are noted in bold.
Abbreviations: GBS, group B Streptococcus; NA, not applicable.
aIncludes unpublished and/or updated data from the investigator group.
Figure 2. Data search and included studies on group B Streptococcus–associated stillbirth.
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Africa (Figure 4). There was moderate heterogeneity between 
studies (I2 = 69%).
Sensitivity Analyses
First, when studies reporting data from all years were included, for 
developed countries the pooled estimate was similar at 2% (95% 
CI, 1%–3%) and for sub-Saharan Africa 4% (95% CI, 1%–7%) 
(Supplementary Figure 1). Second, when studies from developed 
regions were categorized by year periods for median year of data 
collection, the pooled estimate was higher in the earliest studies 
(1961–1978) with a percentage of 6% (95% CI, 3%–10%) in still-
births. The pooled estimate was the same in studies from 1981 to 
2000 at 1% (95% CI, 0–1%) and slightly higher in 2 recent studies 
(2000–2017) at 3% (95% CI, 1%–3%) (Supplementary Figure 2).
Figure 3. Geographic distribution of data on group B Streptococcus (GBS)–associated stillbirth (all years). Borders of countries/territories in map do not imply any political 
statement.
Figure 4. Pooled estimates (with 95% confidence interval [CI]) of proportion of group B Streptococcus (GBS)–associated stillbirth for regions with data since 2000, split by 
region (5 studies, N = 89).
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DISCUSSION
GBS is an important component of the worldwide burden of 2.6 
million stillbirths, accounting for around 1% (95% CI, 0–2%) 
of stillbirths in developed countries and 4% (95% CI, 2%–6%) 
in sub-Saharan Africa. This burden and the opportunities for 
reduction are especially important in Africa, where the num-
ber of stillbirths is high (1.1 million), and approximately 4% are 
associated with GBS disease. In terms of the worldwide mortal-
ity burden of GBS, stillbirths may be far more important than 
neonatal deaths [16].
Estimates are limited, however, by the available data. The stud-
ies have biases in terms of access to care, samples taken, case defi-
nitions, and laboratory methods. Access to care may increase or 
decrease the percentage of GBS-associated stillbirth, depending 
on whether prenatal care reduces GBS-associated stillbirth, or if 
hospital delivery is more likely in mothers who notice a reduc-
tion or a cessation in fetal movements. If samples are not taken 
systematically, with limited numbers of sample sites (such as just 
fetal blood) case ascertainment will be reduced, as GBS could 
be detected in lung aspirate or, possibly, cerebrospinal fluid. In 
Mozambique, the percentage of GBS-associated stillbirth was 
very high (17% [95% CI, 4%–41%]), which may be due to the 
high number of samples taken, increasing the probability of 
detecting GBS [41]. While molecular methods which were used 
would be more sensitive, all of these cases also had GBS isolated 
on conventional culture, so this does not explain the difference.
An important gap is that, for much of the world, there are 
no data on GBS-associated stillbirth, and the wide confidence 
intervals in regions where there are datasets reflect the limited 
data from these areas However, the data gap is particularly 
critical in Asia. In South and Southeast Asia, >1 million of the 
world’s 2.6 million stillbirths occur and there is also uncertainty 
regarding the burden of infant GBS disease. This is reflected by 
lower prevalence of maternal GBS colonization, and possible 
differences in the virulence of GBS strains, with less serotype III, 
commonly associated highly invasive clonal complex 17, iden-
tified [6]. However, this is less applicable to EOGBS and GBS-
associated stillbirth, where there appears from limited data to 
be more diverse serotypes [10, 11]. It is thus possible that there 
is an unrecognized burden of GBS-associated stillbirth and 
EOGBS disease in the first 24 hours after birth, which has not 
been identified with limited data on GBS disease at, or shortly 
after, delivery in South and Southeast Asia where, until recently, 
the majority of births occurred outside of health facilities.
The limited data reflect both the worldwide lack of attention to 
counting stillbirths [4], and to investigation of the causes of still-
birth, even in high-income contexts, where most data on this sub-
ject are historic. The lower prevalence of GBS-associated stillbirth 
reported in more recent data from developed regions is more 
likely to reflect changes in obstetric care, including increased fetal 
monitoring, where signs of fetal distress in utero would lead to 
prompt delivery and treatment. Historically this would have been 
less likely to be detected, as is likely now in low-income and some 
middle-income contexts, which may increase the proportion of 
GBS-associated stillbirth in these contexts, compared to EOGBS 
disease. This may account for more differences between contexts 
than intrapartum antibiotic prophylaxis, which would be likely to 
be given too late to reduce GBS-associated stillbirths.
The data gap for stillbirth is far greater than that for neonates, 
where investigations are more common, although still limited in 
low- and middle-income settings [10, 38]. Improving the data 
on GBS-associated stillbirth is critical in terms both of assessing 
the case for a maternal GBS vaccine and for future maternal 
GBS vaccine trials. Intrapartum antibiotic prophylaxis, used 
to reduce EOGBS disease, is unlikely to be effective for still-
births where infection and death may occur prior to the onset 
of labor. Improving surveillance and research data will require 
standardizing sampling with consensus on the number of sam-
ples taken (and from where), as well as the use of appropriate 
laboratory methods, maximizing sensitivity with conventional 
microbiological methods and assessing the specificity of molec-
ular methods for GBS detection in stillbirth.
CONCLUSIONS
GBS is likely an important, potentially preventable, cause of 
stillbirth, especially in Africa. Improving the data across geog-
raphies, particularly South and Southeast Asia, is important, as 
well as establishing standard investigations and case definitions 
for understanding the burden of disease and for future maternal 
GBS vaccine trials (Table 2).
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Notes
Author contributions. The concept of the estimates and the technical 
oversight of the series was led by J. E. L. and A. C. S. The reviews, analyses 
and first draft of the paper were undertaken by A. C. S. with H. B. and S. A. 
M.  Other specific contributions were made by F.  B. J., N.  E., Q.  B., J.  O., 
Table 2. Key Findings and Implications
What’s new about this?
• These are the first pooled estimates of the percentage of group B 
Streptococcus (GBS)–associated stillbirth, suggesting that 4% of still-
births in Africa may be associated with GBS, and 1% in developed 
regions.
What was the main finding?
• GBS is an important contributor to stillbirth, particularly in Africa. GBS is 
likely to account for more deaths in utero, than after delivery.
How can the data be improved?
• There is a critical need for more data; in terms of the geographies covered, 
particularly in South Asia, and in standardization of sampling strategies, 
laboratory methods, and case definitions.
What does it mean for policy and programs?
• An effective GBS vaccine could prevent stillbirths, especially in low- and 
middle-income contexts.
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